WASHINGTON-Facing Congressional criticism that it isn't doing enough to prevent counterfeit-drug imports, the Food and Drug Administration (FDA) is reviewing thousands of drug shipments from foreign countries. The FDA will be examining the drugs to see if counterfeit ingredients have made their way into US drug-making plants. Congressional concerns stem from the potential of substandard ingredients, manufactured in foreign drug plants, being used by the nation's drug makers. The FDA, while often not inspecting these drugs, says it has no evidence of a substantial problem, nor does it believe that the public is at any risk of harm from such substances. Also part of the investigation is increased enforcement and warnings to importers to help regulators keep track of shipments. For more information, visit www.fda.gov.
“Ongoing Assault”: How HHS Layoffs Have Eviscerated Infection Prevention Support Across the Nation
April 1st 2025Mass layoffs at HHS and CDC have gutted critical infection prevention programs, leaving frontline professionals overwhelmed, under-resourced, and desperate to safeguard public health.
Together We Rise: Why AORN Expo 2025 Is a Must for Every Perioperative Nurse
March 31st 2025From April 5 to 8, 2025, thousands of perioperative nurses will gather in Boston for the 2025 AORN Global Surgical Conference & Expo—a transformational experience designed to elevate nursing practice, build lifelong connections, and advance surgical care.
Vet IP Roundtable 2: Infection Control and Biosecurity Challenges in Veterinary Care
March 31st 2025Veterinary IPs highlight critical gaps in cleaning protocols, training, and biosecurity, stressing the urgent need for standardized, animal-specific infection prevention practices across diverse care settings.